Masimo study finds less than 1% bias and no skin tone discrepancies in neonatal pulse oximetry accuracy. NeoPODS data shows reliable SpO2 readings with minimal hypoxemia cases across diverse newborn ...
Masimo Corp.’s pulse oximetry technology avoids the dangerous under-recognition of low oxygen levels in people of color that plagues many pulse oximeters on the market, a peer-reviewed study in the ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
NEUCHATEL, Switzerland-- (BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results